

Coagulopathy of Immunodermatologic Diseases

NCT06037187

Status RECRUITING
Sponsor University of Nebraska
Enrollment 39 participants

Key Eligibility Criteria

Inclusion (3)

- For the study group: diagnosis of immune-mediated skin disease including but not limited to bullous pemphigoid, pemphigus vulgaris, mucous membrane pemphigoid, cutaneous lupus erythematosus, dermatomyositis
- For control group: no diagnosis of immune-mediated skin
- For study group: receiving care from one or more of the Principal or Secondary Investigators

Exclusion (7)

- Unfit to provide consent
- P2Y12 inhibitor use in the past 4 weeks
- History of internal malignancy prior to enrolling in the study or suspected internal/systemic malignancy during time of the study (i.e. will not exclude pre-malignant or local, early stage cutaneous malignancies)
- Major surgery within 4 weeks of the study or trauma (e.g., accident-causing bone fracture) within 4 weeks of the study
- Other autoimmune diseases not in remission defined as flare in the last 12 weeks
- ... and 2 more (see full listing online)

Locations (1 total)

University of Nebraska Medical Center, Omaha, Nebraska, United States